Group 1: Regulatory Developments - The Hong Kong Monetary Authority (HKMA) has released guidelines for stablecoin issuers, which will be implemented starting August 1, 2025 [1] - Institutions interested in applying for a license are encouraged to contact the HKMA by August 31, 2025, with a deadline for applications set for September 30, 2025 [1] - Predictions suggest that major tech companies like Ant Group and JD.com may be among the first to receive licenses due to their blockchain expertise and application scenarios [1][1] Group 2: Market Performance - The Hong Kong Stock Exchange reported an average daily turnover of HKD 240.2 billion for the first half of 2025, marking a significant year-on-year increase of 118% [5] - The growth in trading volume is attributed to the expansion of the ETF mutual market and the continuous listing of new ETF products, with ETF daily turnover rising to HKD 33.8 billion, a 184% increase year-on-year [5] Group 3: Company Developments - Macau's hotel industry saw an average occupancy rate of 89.1% in the first half of 2025, an increase of 5.1 percentage points year-on-year [6] - In the first half of 2025, Huaneng International Power Co. reported a net profit of approximately RMB 9.262 billion, a year-on-year increase of 24.26% [15] - Youzan expects to achieve a net profit of approximately RMB 68 million to RMB 74 million for the six months ending June 30, 2025, compared to a net loss of RMB 4.295 million in the same period last year [13]

Group 1 - Heartway Medical-B (06609.HK) expects a net profit of no less than RMB 40 million for the six months ending June 30, 2025, a significant turnaround from a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] - The anticipated profit and performance improvement are primarily due to business growth, leading to increased revenue and a decrease in overall expenditure ratio compared to the corresponding period [1] Group 2 - Baoshan International (03813.HK) expects a mid-term net profit of approximately RMB 187.6 million, a year-on-year decrease of 44.1% [2] - Baio Family Interaction (02100.HK) anticipates a mid-term profit increase of approximately 134.9% to 141.6% [2] - Skyworth Group (00751.HK) warns of an expected mid-term post-tax profit decline of about 50% year-on-year [2] Group 3 - China CNR Corporation (01766.HK) recently signed a significant contract worth approximately RMB 32.92 billion [2] - China Power (02380.HK) reported a total electricity sales volume of 11.299 million megawatt-hours in June, a year-on-year decrease of 5.04% [2]

Core Viewpoint - The company InnoCare (02577) has established a joint laboratory with a leading global automotive electronics supplier, United Automotive Electronics Co., Ltd., to develop advanced power electronic systems for new energy vehicles using GaN technology [1] Group 1: Joint Laboratory Establishment - The joint laboratory was formed on July 29, 2025, to leverage the advantages of GaN devices, including high power density, low conduction resistance, high conversion efficiency, and smaller product size [1] - The collaboration aims to combine the company's strengths in GaN technology with United Electronics' expertise in system knowledge to create smaller and lighter power supplies and drive systems for electric vehicles [1] Group 2: Market Impact - The partnership is expected to contribute to the future development of power electronic systems for new energy vehicles, enhancing the overall market offerings [1]

Core Viewpoint - The company InnoCare (02577.HK) announced the establishment of a joint laboratory with a leading global automotive electronics supplier, United Automotive Electronics Co., Ltd., to develop advanced power electronic systems for new energy vehicles using GaN technology [1] Group 1: Joint Laboratory and Collaboration - The joint laboratory aims to leverage the advantages of GaN devices, including high power density, low on-resistance, high conversion efficiency, and smaller product size [1] - The collaboration is expected to combine InnoCare's strengths in GaN technology with United Automotive's expertise in system knowledge, leading to the development of smaller and lighter power systems for electric vehicles [1] Group 2: United Automotive Electronics Co., Ltd. - United Automotive Electronics Co., Ltd. is a joint venture established by Robert Bosch and SAIC Group's subsidiary, which has captured a significant market share in China's automotive engine control units and powertrain systems since its inception in 1995 [1] - The partnership is positioned to enhance the future of power electronic systems in new energy vehicles [1]

Core Viewpoint - InnoCare (02577) has established a joint laboratory with a leading global automotive electronics supplier, United Automotive Electronics Co., to develop advanced power electronic systems for new energy vehicles using GaN technology [1] Group 1: Collaboration and Development - The joint laboratory aims to leverage the advantages of GaN devices, including high power density, low on-resistance, high conversion efficiency, and smaller product size [1] - The collaboration is expected to combine InnoCare's strengths in GaN technology with United Electronics' expertise in system knowledge, leading to the creation of smaller and lighter power supplies and drive systems for electric vehicles [1] - The partnership is positioned to shape the future of power electronic systems in the new energy vehicle market [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 自願公告 與聯合電子成立氮化鎵技術聯合實驗室 本公告由英諾賽科（蘇州）科技股份有限公司（「本公司」）自願作出，旨在使本公司 股東及潛在投資者了解本公司最新業務發展情況。 本公司宣佈，於2025年7月29日，本公司與全球領先的汽車電子系統供應商聯合 汽車電子有限公司（「聯合電子」）成立聯合實驗室，通過利用氮化鎵(GaN)器件在 高功率密度、低導通電阻、高轉換效率和更小的產品尺寸等方面的優勢，合作開 發先進的新能源汽車電力電子系統。 股東及潛在投資者於買賣本公司證券時，務請審慎行事。 承董事會命 英諾賽科（蘇州）科技股份有限公司 董事長兼執行董事 Weiwei Luo博士 中國，20 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 英諾賽科（ 蘇州）科技股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02577 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股 ...

InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 完成根據一般授權配售新H股 及 修訂《公司章程》 獨家整體協調人 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料 ...

Core Viewpoint - InnoCare (stock code: 2577) announced a financing plan through the placement of new H shares, aiming to raise approximately HKD 550 million, with net proceeds expected to be around HKD 540 million after expenses [1] Group 1: Financing Details - The company plans to issue 13,584,000 new H shares at a placement price of HKD 40.50, representing a discount of about 8.9% compared to the previous trading day's closing price of HKD 44.45 [1] - The placement price also reflects a discount of approximately 3.0% compared to the average closing price over the last five trading days [1] - The new shares will account for approximately 1.54% of the existing issued share capital and about 1.52% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 270 million of the proceeds will be allocated for product upgrades and the development of new application technologies [1] - Around HKD 140 million will be used to repay existing interest-bearing bank debts [1] - Another HKD 140 million is designated for working capital and general operational purposes [1] Group 3: Completion Timeline - The issuance is expected to be completed on the first trading day after the fulfillment or waiver of placement conditions, but no later than five days after the placement agreement date or another date agreed upon in writing with the placement agent [1]

Core Viewpoint - InnoCare (02577.HK) has entered into a placement agreement to issue 13.584 million new H-shares at a price of HKD 40.50 per share, aiming to raise approximately HKD 550 million to enhance its financial strength and market competitiveness [1] Group 1: Placement Details - The placement shares represent about 2.77% of the total issued H-shares and approximately 1.54% of the total issued shares as of the announcement date [1] - The estimated total amount raised from the placement, assuming full subscription, is expected to be HKD 550 million, with a net amount of approximately HKD 544 million after deducting commissions and estimated expenses [1] Group 2: Use of Proceeds - Approximately 50% of the funds will be used to support product upgrades and technology research and development to enhance the competitiveness of GaN products [2] - About 25% of the funds will be allocated to repay existing interest-bearing bank debts, improving the company's financial condition and reducing financial expenses [2] - The remaining 25% will be used to supplement working capital and for general operational purposes, including talent recruitment and administrative expenses [2]